

Pulmonary Hypertension Associated with Interstitial Lung Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/P7C82CC0E55BEN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: P7C82CC0E55BEN

Abstracts

The 7 major pulmonary hypertension associated with interstitial lung disease markets reached a value of US\$ 1.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1.6 Billion by 2034, exhibiting a growth rate (CAGR) of 3.99% during 2024-2034.

The pulmonary hypertension associated with interstitial lung disease market has been comprehensively analyzed in IMARC's new report titled "Pulmonary Hypertension Associated with Interstitial Lung Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pulmonary hypertension associated with interstitial lung disease represents a complex and severe medical condition characterized by elevated blood pressure in the pulmonary arteries. It occurs when the lung tissue becomes progressively scarred and inflamed, leading to impaired gas exchange and reduced lung function. As a consequence, the heart must work harder to pump blood through the narrowed pulmonary vessels, resulting in increased pressure on the right side of the heart. The common symptoms of this condition may include breathlessness, fatigue, chest pain, dizziness, swollen ankles, etc. These indications tend to worsen over time, significantly impacting the patient's quality of life. The diagnosis of the ailment is often challenging, as the symptoms may be confused with those of other heart and lung diseases. Physicians typically rely on a combination of physical examination, medical history, and various investigations, including pulmonary function tests, high-resolution computed tomography, an echocardiogram, and right heart catheterization, to diagnose the disorder.

The increasing prevalence of frequent genetic and epigenetic alterations, which can cause scarred and thickened lung tissues, thereby inhibiting oxygen exchange and inducing hypertension in the pulmonary arteries, is primarily driving the pulmonary hypertension associated with interstitial lung disease market. In addition to this, the inflating utilization of effective therapeutic drugs, such as phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostacyclin analogs, etc., that are aimed at managing and decelerating disease progression, is also creating a positive outlook for the market. Moreover, the widespread adoption of oxygen therapy and pulmonary rehabilitation, owing to their numerous benefits, such as enhancing breathing function, physical stamina, and overall quality of life for individuals suffering from the ailment, is further bolstering the market growth. Apart from this, the rising application of advanced interventional procedures, such as balloon pulmonary angioplasty, that dilate narrowed or blocked pulmonary arteries in patients with end-stage disease is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which focuses on delivering functional genetic material into cells to rectify or compensate for the aberrant or defective genes accountable for the illness, is expected to drive the pulmonary hypertension associated with interstitial lung disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the pulmonary hypertension associated with interstitial lung disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pulmonary hypertension associated with interstitial lung disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pulmonary hypertension associated with interstitial lung disease market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the pulmonary hypertension associated with interstitial lung disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the pulmonary hypertension associated with interstitial lung disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current pulmonary hypertension associated with interstitial lung disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status

Clinical Trial Results Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

- How has the pulmonary hypertension associated with interstitial lung disease market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the pulmonary hypertension associated with interstitial lung disease market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the pulmonary hypertension associated with interstitial lung disease market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?

Epidemiology Insights

- What is the number of prevalent cases (2018-2034) of pulmonary hypertension associated with interstitial lung disease across the seven major markets?
- What is the number of prevalent cases (2018-2034) of pulmonary hypertension associated with interstitial lung disease by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of pulmonary hypertension associated with interstitial lung disease by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with pulmonary hypertension associated with interstitial lung disease across the seven major markets?
- What is the size of the pulmonary hypertension associated with interstitial lung disease patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of pulmonary hypertension associated with interstitial lung disease?
- What will be the growth rate of patients across the seven major markets?

Pulmonary Hypertension Associated with Interstitial Lung Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for pulmonary hypertension associated with interstitial lung disease drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pulmonary hypertension associated with interstitial lung disease market?

What are the key regulatory events related to the pulmonary hypertension associated with interstitial lung disease market?

What is the structure of clinical trial landscape by status related to the pulmonary hypertension associated with interstitial lung disease market?

What is the structure of clinical trial landscape by phase related to the pulmonary hypertension associated with interstitial lung disease market?

What is the structure of clinical trial landscape by route of administration related to the pulmonary hypertension associated with interstitial lung disease market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG

DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy

- 7.7.1 Epidemiology Scenario (2018-2023)
- 7.7.2 Epidemiology Forecast (2024-2034)
- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE - UNMET NEEDS

10 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE - KEY ENDPOINTS OF TREATMENT

11 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE - MARKETED PRODUCTS

- 11.1 List of Pulmonary Hypertension Associated with Interstitial Lung Disease Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Tyvaso (Treprostinil)- United Therapeutics Corp

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE - PIPELINE DRUGS

12.1 List of Pulmonary Hypertension Associated with Interstitial Lung Disease Pipeline Drugs Across the Top 7 Markets

- 12.1.1 L-606 - Pharmosa Biopharm
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size

- 15.2.1.1 Market Size (2018-2023)
- 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Pulmonary Hypertension Associated with Interstitial Lung Disease - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Pulmonary Hypertension Associated with Interstitial Lung Disease - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Pulmonary Hypertension Associated with Interstitial Lung Disease - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size
 - 15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Pulmonary Hypertension Associated with Interstitial Lung Disease - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Pulmonary Hypertension Associated with Interstitial Lung Disease - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Pulmonary Hypertension Associated with Interstitial Lung Disease - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Pulmonary Hypertension Associated with Interstitial Lung Disease - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Pulmonary Hypertension Associated with Interstitial Lung Disease - Access and Reimbursement Overview

16 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG

DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Pulmonary Hypertension Associated with Interstitial Lung Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/P7C82CC0E55BEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P7C82CC0E55BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

